IQVIA (IQV)

Health Care · $45.3B market cap · SEC CIK 0001478242

Next reports on Feb 3, 2027, after the close, with analysts expecting $3.62 in earnings per share.

52-week range $154.50 to $284.50. 3% below its 52-week high and 78% above its low.

The case for IQV

• Revenue growing 8.8% year over year.
• Return on equity of 22%.
• Within 3% of its 52-week high: the trend is up.

The case against

• Long-term debt of $13.9B would take 5 years of operating cash flow to repay.
• Current liabilities exceed current assets (ratio 0.83).

What the score is made of

Each factor is half a curve over reported figures and half a rank among the other Health Care companies (momentum is judged against fixed thresholds only), and the five are blended by weight. The score is where that blend places it in the S&P 500. It describes the last filing and the current price. It is not a forecast.

• Each factor except momentum is half fixed thresholds, half rank among the 59 Health Care companies.

The financials

The financials, five years deep

Pulled from IQVIA's XBRL filings on SEC EDGAR. Italic rows are worked out from the others.

What IQVIA says it does

Our Company IQVIA is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI ® , advanced analytics, the latest technologies and extensive domain expertise. We are committed to using artificial intelligence ("AI") responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 93,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, we are dedicated to accelerating the development and commercialization…

Risk factors IQV lists in its 10-K

• The potential loss or delay of our large contracts or of multiple contracts could adversely affect our results
• If we fail to perform our services in accordance with contractual requirements, regulatory standards and ethical considerations, we could be subject to significant costs or liability and our reputation could be harmed
• Improper performance of our services
• Insufficient client funding to complete a clinical trial
• Failure of vendors to perform contractual obligations
• Security breaches and unauthorized use of our IT systems and information, or the IT systems or information in the possession of our vendors, could expose us, our clients, our data suppliers or others to risk of loss
• Failure to meet productivity objectives under our internal business transformation initiatives could adversely impact our competitiveness and harm our operating results
• If we are unsuccessful at investing in growth opportunities, our business could be materially and adversely affected
• Our success depends on our ability to protect our intellectual property rights
• We may be subject to claims by others that we are infringing on their intellectual property rights
• We rely on licenses from third parties to certain technology and intellectual property rights for some of our services and the licenses we currently have could terminate or expire
• Our financial results may be adversely affected if we underprice our contracts, overrun our cost estimates or fail to receive approval for or experience delays in documenting change orders
• The relationship of backlog to revenues varies over time
• We may experience challenges with the acquisition, development, enhancement or deployment of technology necessary for our business
• We may be adversely affected by client or therapeutic concentration
• Our business is subject to international economic, political and other risks that could negatively affect our results of operations and financial condition
• Environmental events may have an impact on our business
• Foreign Currency Risk from Differences in Customer Contract Currency and Operating Costs Currency
• We face risks related to sales to government entities
• If we are unable to successfully develop and market new services or enter new markets, our growth, results of operations or financial condition could be adversely affected
• Our Research & Development Solutions business could subject us to potential liability that may adversely affect our results of operations and financial condition
• Our Commercial Solutions business could result in liability to us if a drug causes harm to a patient. While we are generally indemnified and insured against such risks, we may still suffer financial losses
• Our insurance may not cover all of our indemnification obligations and other liabilities associated with our operations
• If we are unable to attract suitable investigators and patients for our clinical trials, our clinical development business might suffer
• Disruptions in the credit and capital markets and unfavorable general economic conditions could negatively affect our business, results of operations and financial condition
• Our effective income tax rate may fluctuate for a variety of reasons, which may adversely affect our operations, earnings and earnings per share
• Changes in accounting standards issued by the Financial Accounting Standards Board (“FASB”) or other standard-setting bodies may adversely affect our financial statements
• If we are unable to successfully identify, acquire and integrate existing businesses, services and technologies, our business, results of operations and financial condition could be adversely impacted
• Our results of operations may be adversely affected if we fail to realize the full value of our goodwill and acquired intangible assets
• We face risks arising from the restructuring of our operations
• The biopharmaceutical services industry is highly competitive and our business could be materially impacted if we do not compete effectively or rapidly adapt to technological change
• Outsourcing trends in the biopharmaceutical industry and changes in aggregate spending and research and development budgets could adversely affect our operating results and growth rate
• Our business may be materially and adversely impacted by factors affecting the biopharmaceutical and healthcare industries
• We may be affected by healthcare reform and potential additional reforms, which may adversely impact the biopharmaceutical industry and reduce demand for our services or negatively impact our profitability
• Actions by government regulators or clients to limit a prescription’s scope or withdraw an approved drug from the market could adversely affect our business and result in a loss of revenues
• Laws restricting biopharmaceutical sales and marketing practices may adversely impact demand for our services
• Our Research & Development Solutions clients face intense competition from lower cost generic products, which may lower the amount that they spend on our services
• Despite our level of indebtedness, we are able to incur more debt and undertake additional obligations. Incurring such debt or undertaking such additional obligations could further exacerbate the risks to our financial condition
• Restrictive covenants in our other indebtedness may limit our flexibility in our current and future operations, particularly our ability to respond to changes in our business or to pursue our business strategies
• Interest rate fluctuations and our ability to deduct interest expense may affect our results of operations and financial condition
• Provisions of the corporate governance documents of IQVIA could make an acquisition of IQVIA difficult and may prevent attempts by its stockholders to replace or remove its management, even if beneficial to its stockholders
• Our operating results and share price may be volatile, which could cause the value of our stockholders’ investments to decline
• Since we have no current plans to pay regular cash dividends on our common stock, stockholders may not receive any return on investment unless they sell their common stock for a price greater than that which they paid for it

Filings

Other Health Care companies